Who are dacomitinib hydrate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vizimpro.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dacomitinib-hydrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

dacomitinib hydrate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

dacomitinib hydrate (dacomitinib-hydrate) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho. Area: Oncology.

preclinical The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3 Oncology Live · refreshed every 30 min

Target snapshot

dacomitinib hydrate (dacomitinib-hydrate) — Pfizer Inc.. The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
dacomitinib hydrate TARGET	dacomitinib-hydrate	Pfizer Inc.	preclinical	The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho	Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3
Vizimpro	Dacomitinib	Pfizer Inc.	marketed	Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor	Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho class)

Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dacomitinib hydrate — Competitive Intelligence Brief. https://druglandscape.com/ci/dacomitinib-hydrate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing